A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Inclusion Criteria

• •Males and females between 18 and 70 years old
• •Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal to (\>=) 10,000 international units per milliliter (IU/mL)
• •Must have chronic hepatitis C (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin
• •Cannot also be infected with Human Immunodeficiency Virus or hepatitis B
• •Must be judged to be in general good health and able to receive Pegasys® and Copegus®
• •No drug or alcohol abuse in the last year
• •Must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. One of the methods needs to be a 'barrier' method (condom or diaphragm)
• •If you are a woman, you cannot be in this study if you are pregnant or nursing